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Metastatic breast cancer - age has a
significant effect on survival
AS. ALBERTS, G. FALKSON, R. VAN DER MERWE'
Summary
The data on 217 elderly (aged ~ 65 years) and 209 middle-
aged postmenopausal patients with metastatic breast cancer
treated in the Department of Medical Oncology, University of
Pretoria, from 1976 to 1985 were analysed to determine the
effect of age on survival. When considered as a group, the
elderly have a more favourable prognosis (median survival
20,3 months) than the middle-aged (median survival 15,54
months) (p= 0,0457). Multivariate age subset analysis (taking
into account all other major prognostic factors) reveal a
distinct bimodal pattern. The median survival of patients
aged 45 - 54 years is 21,2 months and decreases to 16,2
months for patients aged 55 - 64 years (P= 0,08; Cox model).
The median survival improves again to 24,6 months for
patients aged 64 - 74 years (P= 0,0001; Cox model), followed
by an apparent but non-significant decrease to 17,1 months
in the very old (aged 75 - 84 years) (P = 0,52; Cox model).
The more favourable prognosis in the elderly dictates effective
non-toxic treatment.
S Atr Med J 1991; 79: 239-241.
Breast cancer is the second most common cause of death in the
elderly. The correct initial management of patients with meta-
static breast cancer is of prime importance to ensure prolonged,
meaningful survival without undue toxicity. The natural history
of breast cancer in the elderly is therefore of importance. The
effect of age on the prognosis of metastatic breast cancer is
controversial. Some reports indicate no effect of age on prog-
nosis,l others a worse2,3 and some a bener prognosis with
increasing age.4 Many series have the inherent defect of not
simultaneously considering all important co-variates in order
to delineate exactly the effect of age as an independent factor.
Others do not have enough elderly patients in their series to
reach fIrm conclusions. The present smdy was undertaken in a
large series of elderly patients in which an adequate comparison
with middle-aged postmenopausal patients with metastatic
breast cancer could be made.
Patients and methods
Data on all evaluable elderly patients (~ 65 years) with
metastatic breast cancer seen in the Department of Medical
Oncology, University of Pretoria, from January 1976 to
December 1985 were analysed. All evaluable middle-aged
patients « 65 years of age but post-menopausal) with metasta-'
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tic breast cancer seen in the same period were included in the
analysis as a comparative group.
Factors taken into consideration included: age group, asso-
ciated disease (other medical disorder resulting in little or
severe disability),5 hormone receptor stams, performance stams,
dominant metastatic site, number of metastatic sites, and
treatment. The patient characteristics and treatment are shown
in Table I. There were 217 elderly and 209 middle-aged
patients. The median age of the elderly was 72 years and the
median age of the middle-aged was 57 years. More elderly
patients (13%) had signillcant disability due to associated
disease compared with the middle-aged (1%). There was no
signilicant difference in the incidence of associated disease
within the elderly subgroups. In both groups the oestrogen
receptor (ER) stams was largely unknown (85% and 83%).
Within the elderly group, patients aged 85+ years had a
higher rate of ER positivity (33%) than those aged 75 - 84
years (19%) and those aged 65 - 74 years (9%). The performance
stams (PS) (Eastern Cooperative Oncology Group6) distribution
was similar in the elderly (50%, PSI) and middle-aged (53%,
PSI). The distribution of the dominant metastatic sites were
similar - bone metastases in 32% of the elderly and 30% in
the middle-aged patients.
The number of metastatic sites were comparable, 50% of the
elderly and 49% of the middle-aged had only I metastatic site.
Fifty-three per cent of the elderly were treated with tamoxifen,
while 59% of the middle-aged were treated with cytostatic and
hormonal agents (cyclophosphamide, methotrexate, 5-fluoro-
uracil, prednisone, fluoxymesterone l;Uld tamoxifen was the
most commonly used treatment regimen).
Statistical methods. Descriptive statistics and survival
functions were done with the BMDP L-program using the
Kaplan-Meyer survival curve.7 The Mantel-Cox test8 was
used for survival differences (non-eancer deaths were regarded
as censored observations). The simultaneous effects of several
factors were explored using the Cox proportional hazards
model. 9
Results
There was a signillcant difference in the median survival of
the elderly group (20,3 months) v. that of the middle-aged
(16,54 months) (Mantel-Cox P = 0,0457). Within the elderly
group the median survival of the 65 ~ 74-year-olds was 24,6
months, that of the 75 - 84-year-olds 17,1 months and that of
the 85+ year-olds 39,8 months. Within the middle-aged the
median survival of the 45 - 54-year-olds was 21,2 months and
that of the 55 - 64-year-olds 16,2 months (Table I).
The effect of the other prognostic factors on survival are
also shown in Table I. Signilicant factors favourably influencing
survival are: good PS (elderly and middle-aged P ~ 0,00(1);
bone as dominant metastatic site (elderly P ~ 0,0001, middle-
aged P = 0,0139); and small tumour burden - few metastatic
sites (elderly P = 0,0056, middle-aged P = 0,0089). There was
a signillcant association between treatment and survival in the
elderly patients. Elderly patients treated with hormones only
had a signillcantly bener survival (3 I months) than elderly
patients treated with chemotherapy plus hormones (18,5
months) or chemotherapy only (19,9 months) (P = 0,0054). In
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TABLE I. PATIENTS, TREATMENT CHARACTERISTICS AND SURVIVAL
Elderly patients
No. % Survival (mo.)
Middle-aged patients

































little disability 86 40






PS 0 (no symptoms) 24 11
PS 1 (ambulant) 110 50
PS 2 (in bed 50%) 47 22
PS 3 (iD bed 75%) 21 10




Soft tissue 68 31




4 or more 15 7
Treatment
Chemotherapy only 43 19
Chemotherapy plus
hormones 60 28
Hormones only 114 53
the middle-aged there was no significant difference between
the various treatment groups.
Associated disease and ER status did not have a significant
effect on survival. When exploring the simultaneous effect of
all these factors on survival (with the elderly and the middle-
aged grouped together) it was shown that good PS was the
most imponant favourable factor influencing survival (P ~
0,0001) (Table 11). Bone as dominant metastatic site was
second in imponance (P =0,(01) and older age as a favourable
prognostic factor entered as the third most imponant factor
(P = 0,(07). Fewer metastatic sites (P == 0,037) came fourth in
imponance.
The effect of age on survival was further examined in the
Cox model (Table Ill). This allowed simultaneous considera-
TABLE 11. IMPORTANCE OF PROGNOSTIC
FACTORS FAVOURABLY INFWENCING SURVIVAL































































tion of all the major prognostic factors, thus giving the 'pure'
effect of age. A definite bimodal pattern of survival emerged.
Patients aged 45 - 54 years had a median survival of 21,2
months which decreased to 16,2 months for patients aged 5~ -
64 years (P ~ 0,08; Cox model). The median survival improved
again to 24,6 months in patients aged 65 - 74 years (P ~
0,0001; Cox model) followed by an apparent but non-signifi-
cant decrease to 17, I months in the very old, aged 75 - 84
years (P = 0,5205; Cox model). There were too few patients in
the 85+ year-old group for meaningful comparison.
Discussion
This series consists of a large number of patients treated in the
Department of Medical Oncology, Universiry of Pretoria.
Univariate analysis showed that the elderly as a group had a
more favourable prognosis (median survival 20,3 months) than
the middle-aged (16,54 months) (P = 0,0457). When examining
the effect of age on survival, it is necessary to take into account
all the other major prognostic factors that may influence
survival. In the present series, the other classic factors, such as
PS (P = 0,0001), bone as the dominant metastatic site (elderly
P = 0,0001, middle-aged P = 0,0139), and a small tumour
burden - few metastatic sites (elderly P = 0,0056, middle-
aged P = 0,0089) had similar significance in both the elderly
and the middle-aged. These factors were therefore considered
together with age in a Cox model. Older age emerged as the
third most important favourable prognostic factor (P = 0,007)
after good PS and bone as the dominant metastatic site. Age
subset analysis (with the Cox model) showed a bimodal pattern:
the median survival of patients aged 45 - 54 years (21,2
months) decreases nearly significantly to 16,2 months in
patients aged 55 - 64 years (P = 0,08). The median survival
then increases in the elderly subset, '65 - 74 years, to 24,6
months (P = 0,0001) and this is followed by a non-significant
decrease (P = 0,52) to 17, I months in the age subset 75 - 84
years. This apparent decrease is clearly related to other prog-
nostic factors and does not reflect more aggressive biological
behaviour in the elderly.
ER status was not shown to effect survival in this study.
This is due to the large proportion of patients with unknown
ER status (ER st-atus measurement was rarely performed in
the earlier years of the study). In the patients with known ER
status, there was an increase in ER positivity with age, which
could explain the increase in survival with increasing age.
The recognition of this bimodal pattern explains the con-
flicting results in published reports on the effects of age in
metastatic breast cancer. It is evident that the prognosis varies
according to the selection of age interval. Clark et al.! found
no significant effect of age - which is to be expected as the
dividing point was older or younger than 50 years of age. Nash
et al. 2 described an increase in survival up to the age of 60
years and a decline afterwards, which may fit in with the
bimodal pattern described in this series. No subset analysis
was perfonned in patients> 60 years.
Falkson et al.4 reported on 1168 patients with recurrent
breast cancer. The study on patients entered on Eastern
Cooperative Oncology Group (ECOG) protocols showed that
younger patients (in a Cox proportional hazards model of
survival) had shorter survival times. The predicted median
.survival times after the first recurrence were 491 days for
patients < 35 years of age, 590 days for patients 36 - 45 years,
and 700 days for those> 45 years. In that series there were,
however, only 79 patients> 65 years of age. In the univariate
analysis the 75 patients aged 66 - 80 years had a median
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survival of 22,8 months. This pattern fits well with the present
series. The main difference between the two series is that the
ECOG patients were selected for study and did not have
concomitant other disease (which excluded most elderly patients
for entry on study). The present series included all evaluable
patients seen at a single institution.
Host and Lund3 studied an unselected series of 31594
patients with breast cancer. The only co-variate considered
together with age was stage of disease. They found a decline in
survival in all stages of breast cancer in the age subset of
50 - 74 years. A similar decline was observed in patients aged
55 - 64 years of the present series, but improvement occurred
again in the elderly subset of 65 - 74 years. This subset was
not separately analysed by Host and Lund. 3 Host and Lund3
ascribed the decline in survival after 50 years of age to a
possible change in hormonal balance. Since all our patients
were postmenopausal, this phenomenon is more likely to be a
pure age-related change.
In the present series elderly patients treated with hormones
only (mainly tamoxifen) had a significantly better median
survival (31 months) than patients treated with chemotherapy
only (19,9 months) or chemotherapy plus hormones (18,5
months) (P = 0,0054). In the middle-aged there was no
significant difference between the various treatment groups.
Hormonal treatment is the first line treatment of choice in the
elderly with metastatic breast cancer. This is in agreement
with a randomized trial by Taylor et aI. IO It can be concluded
that as a group the elderly with metastatic breast cancer have a
better overall prognosis than postmenopausal women < 65
years of age as a group. A bimodal pattern is evident when age
subsets are fully analysed - a bener prognosis is seen in the
45 - 54-year-old subset with a decline in prognosis in the
55 - 64-year-old group of patients. An increase in prognosis
again occurs in all further elderly subsets when considered
with multivariate analysis. These fmdings reconfirm the age
influence on prognosis when all elderly patients with adequate
data are included in the analysis. The elderly deserve optimal
non-toxic treatment for metastatic breast cancer.
This work was supported in part by a grant from the National
Cancer Association of South Africa and by the David and Frieda
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